November 06, 2014 06:00 AM Eastern Standard Time
KNOXVILLE, Tenn.--( BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) ( http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will host its quarterly conference call today, Thursday, November 6, 2014 at 4:00 PM EST.
The purpose of the call is to update the market in general and shareholders in particular about developments at the Company. In particular, the Company wishes to discuss the completion of the due diligence audit of the Company's regulatory documents for PV-10 and PH-10. In addition, the Company will update callers on the status of the Memorandum of Understanding (“MOU") it signed with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd. This MOU focuses on a definitive licensing contract.
Further, the Company will discuss its solid financial position, its planned phase 3 clinical trial for PV-10 as a treatment for melanoma, and other scientific and corporate developments.
Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337, approximately 15 minutes before the call. A webcast will also be available at: www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until November 30, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID#13594370. |
